Plasma endothelin in congestive heart failure: Effect of the ACE inhibitor, fosinopril

Cardiovascular Research

Volumn 32, Issue 6, 1996, Pages 1148-1154

  Galatius Jensen, Søren ^a   Wroblewski, Henrik ^a   Emmeluth, Claus ^b   Bie, Peter ^b   Haunsø, Stig ^a   Kastrup, Jens ^a  

^a University Hospital ^*  (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

ACE inhibitors; endothelin; endothelium; heart failure; RAAS

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; FOSINOPRIL; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ENDOTHELINS; EXERCISE TEST; FEMALE; FOSINOPRIL; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 0030461719     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(96)00148-4     Document Type: Article

References (34)

1. Yanagisawa M, Kurihara H, Kimura K, et al. A novel potent vasoconstricting peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
2. Hirata Y, Takagi Y, Fukuda Y. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 78:1989;225-228.
3. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JCJ. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc. 67:1992;719-724.
4. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation. 85:1992;1374-1379.
5. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
6. Hiroe M, Hirata Y, Fujita N, et al. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol. 68:1991;1114-1115.
7. Drexler H. Effect of angiotensin-converting enzyme inhibitors on the peripheral circulation in heart failure. Am J Cardiol. 70:1992;50C-54C.
8. Riegger GA, Kochsiek K. Vasopressin, renin and norepinephrine levels before and after captopril administration in patients with congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 58:1982;300-303.
9. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
10. Effect of enalapril on mortality and the development of heart cailure in asymptomatic patients with reduced left ventricular ejection fractions. NEJM. 327:1992;685-691.
11. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 316:1987;1429-1435.
12. Emori T, Hirata Y, Ohta K, Schichiri M, Marumo F. Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochem Biophys Res Commun 1989;160, 1:93-100.
13. Dohi Y, Hahn A, Boulanger C, Buhler F, Luscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension. 19:1992;131-137.
14. Yoshida H, Nakamura M. Inhibition by angiotensin converting enzyme inhibitors of endothelin secretion from cultured human endothelial cells. Life Sci. 50:1992;pl-195-pl-200.
15. Luscher TF. Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone. Basic Res Cardiol. 88:(suppl 1):1993;15-24.
16. Investigator's Brochure: Fosinopril Sodium. The Bristol-Myers Squibb Pharmaceutical Institute for Medical Research, 1991.
17. Erhardt L, Haunsø S, Luonamanmaki K, et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J. 15:1994;S341.
18. Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med. 306:1982;699-705.
19. Borg G. A ratio scaling method for interindividual comparisons. Rep Inst Appl Psychol Univ Stockholm. 27:1972;1-12.
20. Froelich JW, Thrall JH, Kalff V, Rogers WL, Rabinovitch M. Computer analysis of cardiac radionuclide data. Prog Cardiovasc Dis. 26:1983;43-74.
21. Emmeluth C, Bie P. Effect, release and disposal of endothelin-1 in conscious dogs. Acta Physiol Scand. 146:1992;197-204.
22. Montalescot G, Viossat I, Chabrier PE, et al. Endothelin-1 in patients with coronary heart disease undergoing cardiac catherization. J Am Coll Cardiol. 24.5:1994;1236-1241.
23. Drexler H, Banhardt U, Meinertz T, Wollschlager H, Lehmann M, Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial. Circulation. 79:1989;491-502.
24. Tohmo H, Karanko M, Korpilathi K, Scheinin M, Viinamaki O, Neuvonen P. Enalaprilat in acute intractable heart failure after acute myocardial infarction: a prospective, consecutive sample, before and after trial. Crit Care Med. 22.6:1994;965-973.
25. Rousseau MF, Konstam MA, Benedict CR, et al. Progression of left ventricular dysfunction secondary to coronary disease, sustained neurohormonal activation and effect of ibobamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol. 73:1994;488-493.
26. Townend J, Doran J, Jones S, Davies M. Effect of angiotensin converting enzyme inhibition on plasma endothelin in congestive heart failure. Int J Cardiol. 43:1994;299-304.
27. Bigaud M, Hauss B, Schalk C, Jauch MF, D'Orchymont H. Structure activity relationship of phosphoramidon derivatives for in vivo endothelin converting inhibition. Fundam Clin Pharmacol. 8:(2):1994;155-161.
28. Ahn K, Pan S, Beningo K, Hupe D. A permanent human cell line (EA. hy 926) preserves the characteristics of endothelin converting enzyme from primary human umbilical vein endothelial cells. Life Sci. 56:(26):1995;2331-2341.
29. Townend J, Virk SJS, Qiang FX, Lawson N, Bain RI, Davies M. Lymphocyte beta adrenoceptor upregulation and improved cardiac response to adrenergic stimulation following converting enzyme inhibition in congestive heart failure. Eur Heart J. 14:1993;243-250.
30. Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitors and hydralazine on endothelial function in hypertensive rats. Hypertension. 16:1991;558-563.
31. Levine TB, Olivari MT, Cohn JN. Effects of orthotopic heart transplantation on sympathetic control mechanisms in congestive heart failure. Am J Cardiol. 58:1986;1035-1040.
32. Haas GJ, Wooding-Scott M, Binkley PF, Myerowitz PD, Kelley R, Cody RJ. Effects of successful cardiac transplantation on plasma endothelin. Am J Cardiol. 71:1993;237-240.
33. Love PM, Haynes WG, Webb DJ, McMurray JJ. Anti-endothelin therapy is of potential benefit in heart failure. Circulation 1994;90.4.2:I-547.
34. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.